What is Biovac?
Biovac is a prominent biopharmaceutical company dedicated to the development, manufacturing, and distribution of vaccines and biological products. Formed as a public-private partnership, Biovac is instrumental in enhancing local vaccine production capacities and fortifying national healthcare systems. The company actively engages with international collaborators to integrate cutting-edge technologies, cultivate advanced scientific expertise, and broaden access to critical vaccines throughout Africa, thereby fostering greater health autonomy on the continent.
How much funding has Biovac raised?
Biovac has raised a total of $108.3M across 1 funding round:
Debt
$108.3M
Debt (2026): $108.3M with participation from The European Commission, European Investment Bank, and International Finance
Key Investors in Biovac
The European Commission
The European Commission is the executive branch of the European Union, responsible for proposing legislation, implementing decisions, upholding the EU treaties and managing the day-to-day business of the EU. Its involvement suggests a strong alignment with public health and development goals.
European Investment Bank
The European Investment Bank (EIB) is the lending arm of the European Union, focused on supporting EU policy objectives. Its participation indicates a strategic financial commitment to projects with significant economic and social impact, such as public health infrastructure.
International Finance
International Finance Corporation (IFC) is a global development institution focused on the private sector in developing countries. Its investment in Biovac likely supports the company's efforts to build sustainable local capacity and improve access to essential health products.
What's next for Biovac?
The recent major enterprise-level funding and strategic investment signal a new phase of accelerated growth and expanded operational capacity for Biovac. This substantial backing is expected to fuel advancements in vaccine research and development, scale up manufacturing capabilities, and deepen its impact on public health infrastructure across Africa. The company is poised to leverage this capital to further its mission of ensuring greater self-reliance in vaccine supply and accessibility, potentially solidifying its position as a key player in global health security.
See full Biovac company page
